Shin-ichi Muramatsu

List of Publications by Year
in descending order

165	6,759	66234	71532
papers	citations	42 h-index	76 g-index

191	191	191	8224
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effective Treatment of Adult Parasomnias with Keishikaryukotsuboreito in Four Cases. Internal Medicine, 2022, , .	0.3	1
2	Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Molecular Therapy, 2022, 30, 509-518.	3.7	58
3	Advanced therapeutic strategy for hereditary neuromuscular diseases. Molecular Therapy, 2022, 30, 12-13.	3.7	1
4	Global brain delivery of neuroligin 2 gene ameliorates seizures in a mouse model of epilepsy. Journal of Gene Medicine, 2022, 24, e3402.	1.4	3
5	Retinoic acid receptor beta protects striatopallidal medium spiny neurons from mitochondrial dysfunction and neurodegeneration. Progress in Neurobiology, 2022, 212, 102246.	2.8	3
6	N-Acetyl Transferase, Shati/Nat8l, in the Dorsal Hippocampus Suppresses Aging-induced Impairment of Cognitive Function in Mice. Neurochemical Research, 2022, , 1.	1.6	3
7	Kampo Formula-Pattern Models: The Development of 13 New Clinically Useful Standard Abdominal Pattern Models in the Fukushin Simulator. Frontiers in Pharmacology, 2022, 13, 688074.	1.6	1
8	Shati/Nat8l Overexpression Improves Cognitive Decline by Upregulating Neuronal Trophic Factor in Alzheimerâ€™s Disease Model Mice. Neurochemical Research, 2022, 47, 2805-2814.	1.6	2
9	Intra-cisterna magna delivery of an AAV vector with the GLUT1 promoter in a pig recapitulates the physiological expression of SLC2A1. Gene Therapy, 2021, 28, 329-338.	2.3	7
10	Impairment of cognitive function induced by Shati/Nat8l overexpression in the prefrontal cortex of mice. Behavioural Brain Research, 2021, 397, 112938.	1.2	6
11	Gene Therapy in a Mouse Model of Niemannâ€“Pick Disease Type C1. Human Gene Therapy, 2021, 32, 589-598.	1.4	17
12	Dopaminergic restoration of prefrontal cortico-putaminal network in gene therapy for aromatic <scp>l</scp>-amino acid decarboxylase deficiency. Brain Communications, 2021, 3, fcab078.	1.5	12
13	A novel bipolar syndrome animal model via reduction of Teneurin-4, the protein encoded by ODZ4, in the prefrontal cortex of mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2021, 94, 2-P1-40.	0.0	0
14	Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies. Scientific Reports, 2021, 11, 9322.	1.6	14
15	Schizophrenia-Like Behavioral Impairments in Mice with Suppressed Expression of Piccolo in the Medial Prefrontal Cortex. Journal of Personalized Medicine, 2021, 11, 607.	1.1	8
16	Striatal Shati/Nat8lâ€“BDNF pathways determine the sensitivity to social defeat stress in mice through epigenetic regulation. Neuropsychopharmacology, 2021, 46, 1594-1605.	2.8	14
17	Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease. EMBO Molecular Medicine, 2021, 13, e14712.	3.3	17
18	Reduced Immunogenicity of Intraparenchymal Delivery of Adeno-Associated Virus Serotype 2 Vectors: Brief Overview. Current Gene Therapy, 2021, 21, .	0.9	2

#	Article	IF	Citations
19	Inhibitory effects of Shati/Nat8l overexpression in the medial prefrontal cortex on methamphetamineâ€induced conditioned place preference in mice. Addiction Biology, 2020, 25, e12749.	1.4	23
20	An ultra-stable cytoplasmic antibody engineered for in vivo applications. Nature Communications, 2020, 11, 336.	5.8	22
21	YAP-dependent necrosis occurs in early stages of Alzheimerâ€™s disease and regulates mouse model pathology. Nature Communications, 2020, 11, 507.	5.8	62
22	PcdhÎ² deficiency affects hippocampal CA1 ensemble activity and contextual fear discrimination. Molecular Brain, 2020, 13, 7.	1.3	15
23	Discrimination of prediction models between cold-heat and deficiency-excess patterns. Complementary Therapies in Medicine, 2020, 49, 102353.	1.3	8
24	Prediction Model for Deficiency-Excess Patterns, Including Medium Pattern. Kampo Medicine, 2020, 71, 315-325.	0.1	0
25	Regulatory system of mGluR group II in the nucleus accumbens for methamphetamineâ€induced dopamine increase by the medial prefrontal cortex. Neuropsychopharmacology Reports, 2019, 39, 209-216.	1.1	7
26	Prediction of deficiency-excess pattern in Japanese Kampo medicine: Multi-centre data collection. Complementary Therapies in Medicine, 2019, 45, 228-233.	1.3	8
27	Vulnerability to depressive behavior induced by overexpression of striatal Shati/Nat8l via the serotonergic neuronal pathway in mice. Behavioural Brain Research, 2019, 376, 112227.	1.2	9
28	Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency. Brain, 2019, 142, 322-333.	3.7	116
29	Deletion of Class II ADP-Ribosylation Factors in Mice Causes Tremor by the Nav1.6 Loss in Cerebellar Purkinje Cell Axon Initial Segments. Journal of Neuroscience, 2019, 39, 6339-6353.	1.7	8
30	Tau binding protein CAPON induces tau aggregation and neurodegeneration. Nature Communications, 2019, 10, 2394.	5.8	59
31	In vivoâ€gene therapy for Tay-Sachs and Sandhoff diseases by utilizing AAV9 vector encoding modifiedâ€HEXB. Molecular Genetics and Metabolism, 2019, 126, S78.	0.5	0
32	Alzheimer AÎ² Assemblies Accumulate in Excitatory Neurons upon Proteasome Inhibition and Kill Nearby NAKÎ±3 Neurons by Secretion. IScience, 2019, 13, 452-477.	1.9	13
33	Administration of tetrahydrobiopterin restored the decline of dopamine in the striatum induced by an acute action of MPTP. Neurochemistry International, 2019, 125, 16-24.	1.9	8
34	Face-to-trait inferences in patients with Parkinsonâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 170-178.	0.8	6
35	Artificial association of memory events by optogenetic stimulation of hippocampal CA3 cell ensembles. Molecular Brain, 2019, 12, 2.	1.3	30
36	Electrical Abnormalities in Dopaminergic Neurons of the Substantia Nigra in Mice With an Aromatic L-Amino Acid Decarboxylase Deficiency. Frontiers in Cellular Neuroscience, 2019, 13, 9.	1.8	3

#	Article	IF	Citations
37	Promoting Axon Regeneration in Adult CNS by Targeting Liver Kinase B1. Molecular Therapy, 2019, 27, 102-117.	3.7	29
38	TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. Journal of Clinical Investigation, 2019, 129, 3578-3593.	3.9	32
39	Gene Therapy for Parkinson Disease. The Japanese Journal of Rehabilitation Medicine, 2019, 56, 698-701.	0.0	1
40	Gene therapy for Glut1â€deficient mouse using an adenoâ€associated virus vector with the human intrinsic GLUT1 promoter. Journal of Gene Medicine, 2018, 20, e3013.	1.4	15
41	Targeted expression of step-function opsins in transgenic rats for optogenetic studies. Scientific Reports, 2018, 8, 5435.	1.6	14
42	Probing links between action perception and action production in Parkinson's disease using Fitts' law. Neuropsychologia, 2018, 111, 201-208.	0.7	4
43	A Neuron-Specific Gene Therapy Relieves Motor Deficits in Pompe Disease Mice. Molecular Neurobiology, 2018, 55, 5299-5309.	1.9	28
44	The intellectual disability gene PQBP1 rescues Alzheimerâ€™s disease pathology. Molecular Psychiatry, 2018, 23, 2090-2110.	4.1	41
45	Glucocorticoid receptor-mediated amygdalar metaplasticity underlies adaptive modulation of fear memory by stress. ELife, 2018, 7, .	2.8	15
46	Synapse-specific representation of the identity of overlapping memory engrams. Science, 2018, 360, 1227-1231.	6.0	141
47	Inhibitory effects of accumbal transmembrane protein 168 (TMEM168) on methamphetamine-induced place. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-85.	0.0	0
48	Cognitive dysfunction induced by the deletion of NAA synthase Shati/Nat8l in mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-14.	0.0	0
49	Inhibitory effect of knockdown Piccolo on methamphetamine-induced behavioral changes via dopamine/GABA release in the nucleus accumbens of mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-96.	0.0	0
50	Behavioral and neurochemical analyses in the Piccolo knockdown mice as a new animal model for schizophrenia. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-1-102.	0.0	0
51	Vulnerability of social defeats in the overexpressed striatal SHATI/NAT8L in mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-1-71.	0.0	0
52	Inhibitory effects of Shati/Nat8l overexpression in the medial prefrontal cortex on the methamphetamine induced-CPP in mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-95.	0.0	0
53	Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinsonâ€™s, Alzheimerâ€™s, and psychiatric diseases. Journal of Physiological Sciences, 2017, 67, 11-17.	0.9	14
54	Gene therapy for a mouse model of glucose transporter-1 deficiency syndrome. Molecular Genetics and Metabolism Reports, 2017, 10, 67-74.	0.4	12

#	Article	IF	Citations
55	Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's Disease. Human Gene Therapy Clinical Development, 2017, 28, 74-79.	3.2	109
56	Involvement of the accumbal osteopontin-interacting transmembrane protein 168 in methamphetamine-induced place preference and hyperlocomotion in mice. Scientific Reports, 2017, 7, 13084.	1.6	10
57	Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. The Lancet Child and Adolescent Health, 2017, 1, 265-273.	2.7	96
58	Striatal N-Acetylaspartate Synthetase Shati/Nat8l Regulates Depression-Like Behaviors via mGluR3-Mediated Serotonergic Suppression in Mice. International Journal of Neuropsychopharmacology, 2017, 20, 1027-1035.	1.0	21
59	CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. Scientific Reports, 2017, 7, 4159.	1.6	113
60	Overexpression of transmembrane protein 168 in the mouse nucleus accumbens induces anxiety and sensorimotor gating deficit. PLoS ONE, 2017, 12, e0189006.	1.1	18
61	Freezing of Gait in Parkinsonâ€™s Disease Is Associated with Reduced 6-[¹⁸F]Fluoro-L-m-tyrosine Uptake in the Locus Coeruleus. Parkinson's Disease, 2016, 2016, 1-5.	0.6	18
62	A Novel Reporter Rat Strain That Conditionally Expresses the Bright Red Fluorescent Protein tdTomato. PLoS ONE, 2016, 11, e0155687.	1.1	21
63	RpA1 ameliorates symptoms of mutant ataxin-1 knock-in mice and enhances DNA damage repair. Human Molecular Genetics, 2016, 25, ddw272.	1.4	15
64	An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron. Science Translational Medicine, 2016, 8, 347ra94.	5.8	51
65	Evaluation of 6-¹¹C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with Î²-¹¹C-l-DOPA and ¹⁸F-FDOPA in Parkinson Disease Monkeys. Journal of Nuclear Medicine, 2016, 57, 303-308.	2.8	13
66	<scp>HMGB</scp>1 facilitates repair of mitochondrial <scp>DNA</scp> damage and extends the lifespan of mutant ataxinâ€1 knockâ€in mice. EMBO Molecular Medicine, 2015, 7, 78-101.	3.3	66
67	201. Neuron-Specific Systemic Gene Therapy for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency. Molecular Therapy, 2015, 23, S80.	3.7	0
68	C-11. An Update on Gene Therapy for the Treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency. Molecular Therapy, 2015, 23, S103.	3.7	0
69	Induction of neuronal axon outgrowth by Shati/Nat8l by energy metabolism in mice cultured neurons. NeuroReport, 2015, 26, 740-746.	0.6	11
70	Anterograde C1ql1 Signaling Is Required in Order to Determine and Maintain a Single-Winner Climbing Fiber in the Mouse Cerebellum. Neuron, 2015, 85, 316-329.	3.8	161
71	Na, K-ATPase Î±3 is a death target of Alzheimer patient amyloid-Î² assembly. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4465-74.	3.3	112
72	Benefits of Neuronal Preferential Systemic Gene Therapy for Neurotransmitter Deficiency. Molecular Therapy, 2015, 23, 1572-1581.	3.7	25

#	Article	IF	Citations
73	In utero gene therapy rescues microcephaly caused by Pqbp1-hypofunction in neural stem progenitor cells. Molecular Psychiatry, 2015, 20, 459-471.	4.1	31
74	Mutational and functional analysis of Glucose transporter I deficiency syndrome. Molecular Genetics and Metabolism, 2015, 116, 157-162.	0.5	7
75	Knockdown of Dopamine D2 Receptors in the Nucleus Accumbens Core Suppresses Methamphetamine-Induced Behaviors and Signal Transduction in Mice. International Journal of Neuropsychopharmacology, 2015, 18, pyu038-pyu038.	1.0	14
76	Overexpression of Shati/Nat8l, an N-acetyltransferase, in the nucleus accumbens attenuates the response to methamphetamine via activation of group II mGluRs in mice. International Journal of Neuropsychopharmacology, 2014, 17, 1283-1294.	1.0	29
77	AADC Deficiency. , 2014, , 3-4.		0
78	Regulation of the dopaminergic system in a murine model of aromatic l-amino acid decarboxylase deficiency. Neurobiology of Disease, 2013, 52, 177-190.	2.1	37
79	Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous <scp>AAV</scp>9â€<scp>ADAR</scp>2 delivery to motor neurons. EMBO Molecular Medicine, 2013, 5, 1710-1719.	3.3	61
80	AADC Deficiency. Advances in Pharmacology, 2013, 68, 273-284.	1.2	10
81	Cell Therapy for Parkinsonâ€™s Disease. , 2013, , 193-203.		1
82	Systemic Delivery of Tyrosine-Mutant AAV Vectors Results in Robust Transduction of Neurons in Adult Mice. BioMed Research International, 2013, 2013, 1-8.	0.9	49
83	Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Scientific Reports, 2013, 3, 1472.	1.6	83
84	Intrastriatal gene delivery of GDNF persistently attenuates methamphetamine self-administration and relapse in mice. International Journal of Neuropsychopharmacology, 2013, 16, 1559-1567.	1.0	7
85	Dopamine release via the vacuolar ATPase V0 sector c-subunit, confirmed in N18 neuroblastoma cells, results in behavioral recovery in hemiparkinsonian mice. Neurochemistry International, 2012, 61, 907-912.	1.9	14
86	Preclinical substantia nigra dysfunction in rapid eye movement sleep behaviour disorder. Sleep Medicine, 2012, 13, 102-106.	0.8	31
87	Current status of Kampo medicine curricula in all Japanese medical schools. BMC Complementary and Alternative Medicine, 2012, 12, 207.	3.7	32
88	Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nature Medicine, 2012, 18, 1136-1141.	15.2	139
89	Hsp40 Gene Therapy Exerts Therapeutic Effects on Polyglutamine Disease Mice via a Non-Cell Autonomous Mechanism. PLoS ONE, 2012, 7, e51069.	1.1	38
90	Current Status of Kampo Medicine in Community Health Care. General Medicine, 2012, 13, 37-45.	0.1	12

#	Article	IF	Citations
91	Gene Therapy for Aromatic <scp>l</scp> -Amino Acid Decarboxylase Deficiency. Science Translational Medicine, 2012, 4, 134ra61.	5.8	195
92	Careful clinical observation is essential for diagnosis of Huntington's disease. Arquivos De Neuro-Psiquiatria, 2012, 70, 646-646.	0.3	2
93	AADC gene therapy for Parkinson disease: Four years of follow-up. Neuroscience Research, 2011, 71, e101.	1.0	0
94	A pregnant woman with clinical and radiological findings compatible with posterior reversible encephalopathy syndrome in early pregnancy without discernable underlying disorders: Atypical type of this syndrome?. Journal of Obstetrics and Gynaecology Research, 2011, 37, 1137-1140.	0.6	0
95	Rhabdomyolysis caused by tocolytic therapy with oral ritodrine hydrochloride in a pregnant woman with placenta previa: Is this a rare case with a latent predisposing condition?. Journal of Obstetrics and Gynaecology Research, 2011, 37, 672-672.	0.6	1
96	Subregional 6-[18F]fluoro-ÊŸ-m-tyrosine Uptake in the Striatum in Parkinson's Disease. BMC Neurology, 2011, 11, 35.	0.8	19
97	Compensatory Regulation of Dopamine after Ablation of the Tyrosine Hydroxylase Gene in the Nigrostriatal Projection. Journal of Biological Chemistry, 2011, 286, 43549-43558.	1.6	23
98	GENE THERAPY FOR PARKINSON'S DISEASE: STRATEGIES FOR THE LOCAL PRODUCTION OF DOPAMINE. Gene Therapy and Regulation, 2010, 05, 57-65.	0.3	3
99	Gene therapy in Alzheimerâ€™s disease â€“ potential for disease modification. Journal of Cellular and Molecular Medicine, 2010, 14, 741-757.	1.6	63
100	A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease. Molecular Therapy, 2010, 18, 1731-1735.	3.7	290
101	Amelioration of neurological phenotypes and inclusion body formation in polyglutamine disease mice upon AAV5-mediated expression of aggregate inhibitor molecules. Neuroscience Research, 2010, 68, e94.	1.0	0
102	Retinoid X Receptor Gamma Control of Affective Behaviors Involves Dopaminergic Signaling in Mice. Neuron, 2010, 66, 908-920.	3.8	65
103	The current status of gene therapy for Parkinson's disease. Annals of Neurosciences, 2010, 17, 92-5.	0.9	12
104	Ablation of NMDA Receptors Enhances the Excitability of Hippocampal CA3 Neurons. PLoS ONE, 2009, 4, e3993.	1.1	35
105	Nurr1 Is Required for Maintenance of Maturing and Adult Midbrain Dopamine Neurons. Journal of Neuroscience, 2009, 29, 15923-15932.	1.7	320
106	Isolation and Characterization of Patient-derived, Toxic, High Mass Amyloid Î²-Protein (AÎ²) Assembly from Alzheimer Disease Brains. Journal of Biological Chemistry, 2009, 284, 32895-32905.	1.6	162
107	A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies. Annals of Clinical Biochemistry, 2009, 46, 508-510.	0.8	18
108	The cardiac pacemaker-specific channel Hcn4 is a direct transcriptional target of MEF2. Cardiovascular Research, 2009, 83, 682-687.	1.8	41

#	Article	IF	Citations
109	Multitracer assessment of dopamine function after transplantation of embryonic stem cellâ€derived neural stem cells in a primate model of Parkinson's disease. Synapse, 2009, 63, 541-548.	0.6	46
110	A phase 1 trial of gene delivery of aromatic L-amino acid decarboxylase for Parkinson disease. Neuroscience Research, 2009, 65, S24.	1.0	0
111	ERas is Expressed in Primate Embryonic Stem Cells but not Related to Tumorigenesis. Cell Transplantation, 2009, 18, 381-389.	1.2	15
112	Self-Contained Induction of Neurons from Human Embryonic Stem Cells. PLoS ONE, 2009, 4, e6318.	1.1	13
113	Selective loss of nigral dopamine neurons induced by overexpression of truncated human Î±-synuclein in mice. Neurobiology of Aging, 2008, 29, 574-585.	1.5	146
114	Protection Against Aminoglycoside-induced Ototoxicity by Regulated AAV Vectorâ€“mediated GDNF Gene Transfer Into the Cochlea. Molecular Therapy, 2008, 16, 474-480.	3.7	39
115	Variation in the Incidence of Teratomas after the Transplantation of Nonhuman Primate ES Cells into Immunodeficient Mice. Cell Transplantation, 2008, 17, 1095-1102.	1.2	19
116	Acupuncture and Knee Osteoarthritis. Annals of Internal Medicine, 2007, 146, 147.	2.0	1
117	Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Journal of Neuroscience Research, 2007, 85, 1752-1761.	1.3	42
118	Improved Safety of Hematopoietic Transplantation with Monkey Embryonic Stem Cells in the Allogeneic Setting. Stem Cells, 2006, 24, 1450-1457.	1.4	51
119	Viral-Mediated Temporally Controlled Dopamine Production in a Rat Model of Parkinson Disease. Molecular Therapy, 2006, 13, 160-166.	3.7	54
120	Gene Therapy for Parkinson Disease(<SPECIAL ISSUE>Parkinson Disease). Japanese Journal of Neurosurgery, 2006, 15, 756-760.	0.0	0
121	4.Gene Therapy for Parkinson's Disease(PS-9 Parkinson's Disease:To Overcome Side-effects of Dopa,The) Tj ETQq1 1 0.784314 rgBT /Ov Neurosurgery, 2006, 15, 328.	0.0	0
122	Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Annals of Neurology, 2005, 57, 832-842.	2.8	86
123	Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice. Journal of Virology, 2005, 79, 214-224.	1.5	299
124	Specific and efficient transduction of cochlear inner hair cells with recombinant adeno-associated virus type 3 vector. Molecular Therapy, 2005, 12, 725-733.	3.7	105
125	Efficient and stable Sendai virus-mediated gene transfer into primate embryonic stem cells with pluripotency preserved. Gene Therapy, 2005, 12, 203-210.	2.3	19
126	Gene therapy for Parkinsonâ€™s disease using recombinant adeno-associated viral vectors. Expert Opinion on Biological Therapy, 2005, 5, 663-671.	1.4	15

#	Article	IF	Citations
127	Presynaptic Localization of Neprilysin Contributes to Efficient Clearance of Amyloid-Â Peptide in Mouse Brain. Journal of Neuroscience, 2004, 24, 991-998.	1.7	222
128	Efficient gene transfer of a simian immuno-deficiency viral vector into cardiomyocytes derived from primate embryonic stem cells. Journal of Gene Medicine, 2003, 5, 921-928.	1.4	9
129	Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport. Neuroscience Research, 2003, 45, 33-40.	1.0	66
130	Gene Therapy with Virus Vectors for specific Disease of the Nervous System. International Review of Neurobiology, 2003, 55, 205-222.	0.9	3
131	Gene therapy of Parkinson's disease: AAV vectors for delivery of therapeutic genes into mammalian brains. Ensho Saisei, 2003, 23, 218-222.	0.2	0
132	Behavioral Recovery in a Primate Model of Parkinson's Disease by Triple Transduction of Striatal Cells with Adeno-Associated Viral Vectors Expressing Dopamine-Synthesizing Enzymes. Human Gene Therapy, 2002, 13, 345-354.	1.4	182
133	Highly Efficient Gene Transfer into Primate Embryonic Stem Cells with a Simian Lentivirus Vector. Molecular Therapy, 2002, 6, 162-168.	3.7	41
134	Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Therapy, 2002, 9, 381-389.	2.3	164
135	Gene Therapy for Mitochondrial Disease by Delivering Restriction Endonuclease SmaI into Mitochondria. Journal of Biomedical Science, 2002, 9, 534-541.	2.6	106
136	Neuroprotective Effects of Glial Cell Line-Derived Neurotrophic Factor Mediated by an Adeno-Associated Virus Vector in a Transgenic Animal Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2002, 22, 6920-6928.	1.7	244
137	Adeno-associated virus vectors for gene transfer to the brain. Methods, 2002, 28, 237-247.	1.9	31
138	Gene therapy for mitochondrial disease by delivering restriction endonucleaseSmaI into mitochondria. Journal of Biomedical Science, 2002, 9, 534-541.	2.6	151
139	Recombinant adeno-associated viral vectors bring gene therapy for Parkinson's disease closer to reality. Journal of Neurology, 2002, 249, 1-1.	1.8	9
140	Gene Therapy for Parkinsonâ€™s Disease Using Aav Vectors. Advances in Behavioral Biology, 2002, , 459-462.	0.2	0
141	Choreiform movements in spinocerebellar ataxia type 1. Journal of the Neurological Sciences, 2001, 187, 103-106.	0.3	20
142	Recombinant adeno-associated virus vector-transduced vascular endothelial cells express the thrombomodulin transgene under the regulation of enhanced plasminogen activator inhibitor-1 promoter. Gene Therapy, 2001, 8, 1690-1697.	2.3	16
143	Effects of Senkyu-chacho-san on Motor Symptoms in Patients with Parkinson's Disease. Kampo Medicine, 2001, 51, 1087-1091.	0.1	0
144	Sonographic detection of diffuse peripheral nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Clinical Ultrasound, 2000, 28, 488-491.	0.4	61

#	Article	IF	Citations
145	Triple Transduction with Adeno-Associated Virus Vectors Expressing Tyrosine Hydroxylase, Aromatic-L-Amino-Acid Decarboxylase, and GTP Cyclohydrolase I for Gene Therapy of Parkinson's Disease. Human Gene Therapy, 2000, 11, 1509-1519.	1.4	191
146	Sonographic detection of diffuse peripheral nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Clinical Ultrasound, 2000, 28, 488-491.	0.4	3
147	Gene therapy of Parkinsonâ€™s disease using Adeno-Associated Virus (AAV) vectors. , 2000, , 181-191.		10
148	Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. Journal of General Virology, 2000, 81, 2077-2084.	1.3	105
149	Maternal anticipation in Machado-Joseph disease (MJD): some maternal factors independent of the number of CAG repeat units may play a role in genetic anticipation in a Japanese MJD family. Journal of the Neurological Sciences, 1998, 155, 141-145.	0.3	8
150	Transcription-positive cofactor 4 enhances rescue of adeno-associated virus genome from an infectious clone.. Journal of General Virology, 1998, 79, 2157-2161.	1.3	6
151	Nucleotide Sequencing and Generation of an Infectious Clone of Adeno-Associated Virus 3. Virology, 1996, 221, 208-217.	1.1	160
152	Enhancement of murine bone marrow macrophage differentiation by beta- endorphin. Blood, 1995, 86, 1316-1321.	0.6	20
153	Potential Changes within the Basal Ganglia during Putamenâ€“Induced Dystonia and Caudate-Induced Locomotor Hyperactivity in the Freely Moving Cat. Advances in Behavioral Biology, 1994, , 327-336.	0.2	1
154	Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin. Biochemistry, 1993, 32, 2314-2320.	1.2	24
155	List of Serials in the Field of â€œToyo-Igakuâ€•(Oriental Medicine) indexed in JMEDICINE. Kampo Medicine, 1993, 43, 571-575.	0.1	0
156	Regulatory Role of the GTP-Binding Protein, Go, in the Mechanism of Exocytosis in Adrenal Chromaffin Cells. Journal of Neurochemistry, 1992, 58, 2275-2284.	2.1	63
157	Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator.. Journal of Clinical Investigation, 1992, 90, 67-76.	3.9	38
158	Differential roles of the caudate nucleus and putamen in motor behavior of the cat as investigated by local injection of GABA antagonists. Neuroscience Research, 1991, 10, 34-51.	1.0	58
159	An A alpha Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation. Journal of Biological Chemistry, 1991, 266, 11575-11581.	1.6	45
160	Clinical Study of Scalloped Tongue.. Kampo Medicine, 1991, 42, 31-35.	0.1	2
161	Fibrinogens Hamasaka and Tokyo III. Japanese Journal of Thrombosis and Hemostasis, 1991, 2, 286-292.	0.1	0
162	An A alpha Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation. Journal of Biological Chemistry, 1991, 266, 11575-81.	1.6	38

#	Article	IF	Citations
163	Hereditary antithrombin III deficiency with a superior sagittal sinus thrombosis: Evidence for a possible mutation starting in the mother of the propositus. Thrombosis Research, 1990, 57, 593-600.	0.8	13
164	Electrophysiological study of dyskinesia produced by microinjection of picrotoxin into the striatum of the rat. Neuroscience Research, 1990, 7, 369-380.	1.0	29
165	Role of the basal ganglia in manifestation of rhythmical jaw movement in rats. Brain Research, 1990, 535, 335-338.	1.1	32